Gene therapy in the CNS

Gene Therapy

Volumn 7, Issue 2, 2000, Pages 93-109

  Costantini, L C ^a   Bakowska, J C ^b,c   Breakefield, X O ^b,c   Isacson, O ^a  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain tumor; Huntington's disease; Ischemia; Lysosomal storage disease; Parkinson's disease; Vector

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; LEVODOPA; LIPOSOME;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; BRAIN ISCHEMIA; BRAIN TUMOR; CELL TYPE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE COURSE; EPILEPSY; EPSTEIN BARR VIRUS; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC STABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; HUNTINGTON CHOREA; LYSOSOME STORAGE DISEASE; MITOSIS; MOLECULAR BIOLOGY; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; RETROVIRUS; REVIEW; SAFETY; SYMPTOM; TRANSGENE; VIRUS RECOMBINANT;

EID: 0033968031     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301119     Document Type: Review

References (243)

1. Bowers W, Howard D, Federoff H. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp Neurol 1997; 144: 58-68.
2. Raymon H, Thode S, Gage F. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 1997; 144: 82-91.
3. Carter BS, Zervas NT, Chiocca EA. Neurogenetic surgery, current limitations and the promise of gene- and virus-based therapies. Clin Neurosurg 1999; 45: 226-246.
4. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 1999; 56: 445-448.
5. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
6. Haque N, Isacson O. Antisense gene therapy for neurodegenerative disease? Exp Neurol 1997; 144: 139-146.
7. Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
8. Parr MJ et al. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neuroviral 1998; 4: 194-203.
9. Yang W, Mason W, Summers J. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol 1996; 70: 4567-4575.
10. Ho DY, McLaughlin JR, Sapolsky RM. Inducible gene expression from defective herpes simplex virus vectors using tetracycline responsive promoter system. Mol Brain Res 1996; 41: 200-209.
11. Lu B, Federoff HJ. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 1995; 6: 419-428.
12. Manome Y et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9: 1409-1417.
13. Oligino T et al. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Therapy 1998; 5: 491-496.
14. Ye X et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
15. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
16. Klein RL et al. Neuron-specific transduction in the rat eptohippocampla or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 183-194.
17. Peel AL et al. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 1997; 4: 16-24.
18. Song S et al. An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J Neurochem 1997; 68: 1792-1803.
19. Bilang-Bleuel A et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1997; 94: 8818-8823.
20. Davar G et al. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J Comp Neurol 1994; 339: 3-11.
21. Maidment NT et al. Expression of the lacZ reporter gene in the rat basal forebrain, hippocampus and nigrostriatal pathway using a nonreplicating herpes simplex virus. Exp Neurol 1996; 139: 107-114.
22. Herrlinger U et al. HSV-1 vectors for therapy of experimental CNS tumors. In: Methods in Molecular Medicine, Gene Therapy Protocols. Human Press Inc: Totowa, NJ (in press).
23. Dewey RA et al. Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Med 1999; 5: 1256-1263.
24. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields Virology. Lippincott-Raven: Philadelphia, 1996, pp 2231-2296.
25. Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 1997; 136: 1007-1021.
26. Bearer EL et al. Squid axoplasm supports the retrograde axonal transport of herpes simplex virus. Biol Bull 1999; 197: 257-258.
27. Jacobs A et al. Functional co-expression of HSV-1 thymidine kinase and green fluorescent protein (TKGFP): implications for imaging therapeutic gene expression. Neoplasia (in press).
28. Glorioso JC et al. Herpes simplex virus as a gene-delivery vector for the central nervous system. In: Viral Vectors 1-23. Academic Press: New York, 1995.
29. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
30. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998; 72: 5919-5926.
31. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
32. Ho DY, Mocarski ED. Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse. Virology 1988; 167: 279-283.
33. Goins B, Rudolph AS, Ligler FS. Liposome-encapsulated hemoglobin: historical development of a blood substitute. Biotech 1991: 19: 117-125.
34. Dobson AT et al. A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron 1990; 5: 353-360.
35. Spaete R, Frenkel N. The herpes virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
36. Fraefel C et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
37. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
38. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7173-7143.
39. Constantini L et al. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 1999; 10: 2481-2494.
40. Wang AU et al. HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes. Am J Phys (in press).
41. Fraefel C, Jacoby DR, Breakefield XO. Recent developments un herpes simplex virus type 1-based amplicon vector systems. In: Advances in Virus Research. Academic Press: New York (in press).
42. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Topics Microbiol/Immunol 1992; 148: 97-129.
43. Xiao X et al. Adeno-associate virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha 1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997; 756: 76-83.
44. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
45. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71: 3299-3306.
46. Walker SL, Wondreling RS, Owens RA. Mutational analysis of the adeno-associated virus Rep68 protein: identification of critical residues necessary for site-specific endonuclease activity. J Virol 1997; 71: 2722-2730.
47. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91: 5808-5812.
48. Yang CC et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997; 71: 9231-9247.
49. Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nature Med 1997; 3: 1295-1297.
50. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
51. Summerford C, Samulski R. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 assembly. J Virol 1998; 72: 1438-1445.
52. Grimm D, Kern A, Rittner K, Kleinschmidt J. Novel tools for produclion and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
53. Bartlett JS, Samulski RJ, McCown T. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 1998; 9: 1181-1186.
54. Kaplitt MG et al. Proenkephalin promoter yield region-specific and long-term expression in adult brain after in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 1994, 91: 8979-8983.
55. Mandel RJ et al. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998; 18: 4271-4284.
56. Lo W et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999; 10: 201-213.
57. McCown TJ et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
58. Bartlett J, Kienschmidt J, Boucher R, Samulski R. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′gamma)2 antibody. Nat Biotechnol 1999; 17: 181-186.
59. Girod A et al. Genetic capsid modification allow efficient retargeting of adeno-associated virus type 2. Nature Med 1999; 5: 1052-1056.
60. Haberman R, McCown T, Samulski R. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Therapy 1998; 5: 1604-1611.
61. Rivera V et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 1999; 96: 8657-8662.
62. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
63. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
64. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030-7038.
65. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
66. Armentano D et al. E40RF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J Virol 1999; 8: 7031-7034.
67. Ilan Y et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94: 2587-2592.
68. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 10: 1217-1229.
69. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
70. Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Therapy 1997; 4: 393-400.
71. Fang B et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Therapy 1996; 3: 217-222.
72. Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
73. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
74. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
75. Morsy MA et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
76. Kumar-Singh R, Farber DB. Encapsiclated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Hum Mol Genet 1998; 7: 1893-1900.
77. Lieber A, He CY, Kay MA. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 1997; 15: 1383-1387.
78. Thomas CE et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity adenovirus vectors: towards realistic long-term neurological gene therapy for chronic diseases (submitted).
79. Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999; 73: 6141-6146.
80. Overturf K et al. Adenovirus-mediated gene therapy in a mouse model of heriditary tyrosinemia type I. Hum Gene Ther 1997; 8: 513-521.
81. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology, 3rd edn. Lippincott Raven Publishers: Philadelphia, 1996, pp 2149-2173.
82. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
83. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
84. Cepko CL et al. Lineage analysis using retroviral vectors. Curr Top Dev Biol 1998; 36: 51-74.
85. Bankiewicz KS et al. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp Neurol 1997; 114: 147-156.
86. Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends in Neurosci 1997; 20: 530-538.
87. Fisher L et al. Survival and function of intrastriatally grafted fibroblasts genetically modified to produce L-dopa. Neuron 1990; 6: 371-380.
88. Johnston K et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-370.
89. Sena-Esteves M et al. Single step conversion of cells to retrovirus vector producers with HSV/EBV hybrid amplicons. J Virol 1999; 73: 10426-10439.
90. Palombo F et al. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol 1998; 72: 5025-5034.
91. Wang S, Vos J-M. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 1996; 70: 8422-8430.
92. Yates J, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
93. Recchia A et al. Site-specific integration mediated by a hybrid adenovirus-adeno-associated virus vector. Proc Natl Acad Sci USA 1999; 96: 2615-2620.
94. Fisher K et al. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7: 2079-2087.
95. Bilbao G et al. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEBJ 1997; 11: 624-634.
96. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
97. Naldini L et al. In vivo delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 1996; 272: 263-267.
98. Kafri T et al. Sustained expression of genes delivery directly into the liver and muscle by lentiviral vectors. Nat Genet 1997, 17: 314-317.
99. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
100. Zufferey R et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
101. Kafri T et al. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.
102. Miyoshi H et al. Development of a self-inactivating lentivirus vector. J Virus 1998; 72: 8150-8157.
103. Iwakuma T, Cui Y, Chang L. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virol 1999; 26: 120-132.
104. White S et al. Lentivirus vectors using human and simian immunodeficiency virus 1 elements. J Virol 1999; 73: 2832-2840.
105. Blömer U et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649.
106. Jiao S, Cheng L, Wolff JA, Yang NS. Particle bombardment-mediated gene transfer and expression in rat brain tissues. Biotech 1993; 11: 497-502.
107. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
108. Wagner E et al. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992; 89: 6099-7103.
109. Huckett B, Ariatti M, Hawtrey AO. Evidence for targeted gene transfer by receptor-mediated endocytosis. Stable expression following insulin-directed entry of NEO into HepG2 cells. Biochem Pharmacol 1990; 40: 253-263.
110. Wagner E, Cotten M, Foisner R, Birnstiel ML. Transferrin-polycation-DNA complexes' the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA 1991; 88: 4255-4259.
111. Saeki Y et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8: 2133-2141.
112. Aronsohn AI, Hughes JA. Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy. J Drug Target 1998; 5: 163-169.
113. Namiki Y, Takahashi T, Ohno T. Gene transduchon for disseminated intraperitoneal tumor using cationic liposomes containing non-histone chromatin proteins: cationic liposomal gene therapy of carcinomatosa. Gene Therapy 1998; 5: 240-246.
114. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes- the best of both worlds? Mol Med Today 1999; 5: 298-303.
115. Schwartz B et al. Gene transfer by naked DNA into adult mouse brain. Gene Therapy 1996; 3: 405-411.
116. Brooks AI et al. Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. J Neurosci Meth 1998; 80: 137-147.
117. Rainov NG, Breakefield XO, Kramm CM. Routes of vector application for brain tumor gene therapy. Gene Therapy and Mol Biology (in press).
118. Muldoon LL et al Delivery of therapeutic agents to brain and intracerebral tumors. In: Chiocca EA, Breakefiold XO (eds). Gene Therapy for Neurologic Diseases. Humana Press: Boston, MA, 1998, pp 295-311.
119. Short MP et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-439.
120. Goldsmith KT, Curiel DT, Engler JA, Garver RIJ. Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther 1994; 5: 1341-1348.
121. Boviatsis EJ et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus (HSV), and retrovirus vectors. Hum Gene Ther 1994; 5: 183-191.
122. Aboody KS et al. A new platform for gene therapy against brain tumors: foreign gene expressing neural stem cells display tropism for intracranial gliomas (submitted).
123. Gage FH. Stem cells of the central nervous system. Curr Opin Neurobiol 1998; 8: 671-676.
124. Lal B et al. Endothelial cell implantation and survival within experimental gliomas. Proc Natl Acad Sci USA 1994; 91: 9695-9699.
125. Uteza Y et al. Intravitreous transplantation of encapsulated fibroblasts secreting the human fibroblast growth factor 2 delays photoreceptor cell degeneration in Royal College of Surgeons rats. Proc Natl Acad Sci USA 1999; 96: 3126-3131.
126. Kramm CM et al Herpes vector-mediated delivery of thymidine kinase gene to disseminated CNS tumors. Hum Gene Ther 1996; 7: 291-300.
127. Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374: 367-370.
128. Muldoon LL et al. Comparison of intracerebral inoculation and osmotic blood brain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide particles to normal rat brain. Am J Pathol 1995; 147: 1840-1851.
129. Nilaver G et al. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 1995; 92: 9829-9833.
130. Rainov NG et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 1995; 6: 1543-1552
131. Rainov NG et al. Long term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes-simplex virus vector. Cancer Gene Ther 1998; 5: 158-162.
132. Barnett FH et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther 1999; 6: 14-20.
133. Inamura T, Black K. Bradykinin selectively opens blood tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994; 14: 862-870.
134. Miller CR et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748.
135. Jin BK et al. Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector Hum Gene Ther 1996; 7: 2015-2024.
136. Brenner M et al. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 1994; 14: 1030-1037.
137. Szklarczyk A, Kaczmarek L. Brain as a unique antisense environment. Antisense Nucleic Acid Drug Dev 1999; 9: 105-116.
138. Cui J, Hsu C, Liu P. Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligonucleotide. J Neurosci 1999; 19: 1335-1344.
139. Boado R, Tsukamoto H, Pardridge W. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci 1998; 87: 1308-1315.
140. Martres M et al. Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain. Eur J Neurosci 1998; 10: 3607-3616.
141. Dunnett S, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399: 32-39.
142. During M, Naegele J, O'Malley K, Geller A. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
143. During MJ et al. In vivo expression of therapeutic human genes for dopamine production in the caudate of MPTP-treated monkeys using an AAV vector. Gene Therapy 1998; 5: 820-827.
144. Horellou P et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994; 6: 49-53.
145. Fitoussi N et al. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes. Neuroscience 1998; 85: 405-413.
146. Horellou P, Brundin P, Mallet J, Bjorklund A. In vivo release of dopa and dopamine from genetically-engineered cells grafted to the denervated rat striatum. Neuron 1990; 5: 393-402.
147. Lundberg C, Horellou P, Mallet J, Bjorklund A. Generation of dopa-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene - in vitro characterization and in vivo effects in the rat parkinson model. Exp Neurol 1996; 139: 39-53.
148. Trejo F, Vergara P, Brenner M, Segovia J. Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci 1999; 65: 483-491.
149. Wolfe J, Fisher L, Xu L Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1989; 86: 9011-9014.
150. Kang U et al. Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci 1993; 13: 5203-5211.
151. Cao L et al. Gene therapy of Parkinson's disease model rat by direct injection of plasmid DNA-lipofectin. Hum Gene Ther 1995; 6: 1497-1501.
152. Imaoka T, Date I, Ohmoto T, Nagatsu T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 1998; 9: 1093-1102.
153. Segovia J, Vergara P, Brenner M. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Therapy 1998; 5: 1650-1655.
154. Bencsics C et al. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-dopa by primary fibroblasts. J Neurosci 1996; 16: 4449-4456.
155. Leff S et al. In vivo L-dopa production by genetically modified primary rat fibroblasts or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosine hydroxylase. Exp Neurol 1998; 151: 249-264.
156. Wachtel S, Bencsics C, Kang U. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J Neurochem 1997; 69: 2055-2063.
157. Fan D et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by contransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2527-2535.
158. Lee W, Chang J, Nemeth N, Kang U. Vesicular monoamine transporter-2 and aromatic L-amino-acid decarboxylase enhance dopamine delivery after L-3/4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci 1999; 19: 3266-3274.
159. Leff S, Spratt S, Snyder R, Mandel R. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999; 92: 185-196.
160. Tsacson O. Behavioral effects and gene delivery in a rat model of Parkinson's disease; technical comments. Science 1995; 269: 856-857.
161. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998; 152: 259-277.
162. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995; 15: 3863-3875.
163. Zhou Q, Palmiter R. Dopamine-deficient mice are severely hypokinetic, adipsic, and aphagic. Cell 1995; 83: 1197-1209.
164. Szczypka M et al. Viral gene delivery selectively restores feeding and prevents lethaity of dopamine-deficient mice. Neuron 199; 22: 167-178.
165. Bohn M. A commentary on glial cell line-derived neurotrophic factor (GDMF). From a glial secreted molecule to gene therapy. Biochem Pharmacol 1999; 57: 135-142.
166. Choi-Lundberg DL et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275: 838-841.
167. Lapchak PA et al. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 1997; 777: 153-160.
168. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997; 9: 14083-14088.
169. Galpern WR et al Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 1996; 5: 225-232.
170. Levivier M, Przedborski S, Bencsics C, Kang U. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995; 15: 7810-7829.
171. Lindner M et al. Implantation of encapsulated catecholamine and GDNF producing cells in rats with unilateral dopamine depletions and Parkinsonian symptoms. Exp Neurol 1995; 132: 62-76.
172. Yoshimoto Y et al. Astrocytes retrovirally transduced with BDNF elicity behavioral improvement in a rat model of Parkinson's disease. Brain Res 1995; 691: 25-36.
173. Frim DM et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in rat. Proc Natl Acad Sci USA 1994; 91: 5104-5108.
174. Yamada M et al. Herpes simplex virus vector-mediated expression of bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999; 96: 4078-4083.
175. Wexler N et al. Homozygotes for Huntington's disease. Nature 1997; 161: 223-226.
176. Isacson O, Hague N. Gene therapy of Huntington's disease. In: Breakefield XO (ed) Gene Transfer and Therapy for Neurological Disorders. The Humana Press: New Jersey, 1988, pp 423-440
177. Spokes E. Neurochemical alterations in Huntington's Chorea. A study of postmortem brain tissue. Brain 1980; 103: 179-210.
178. Kordower J, Isacson O, Emerich D. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp Neurol 1999; 159: 4-20.
179. Schumacher J et al. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 1991; 45: 561-570.
180. Kordower J et al. Grafts of EGF-responsive neural stem cells derived from GFAP-gBGF transgenic mice: trophic and tropic effects in a rodent model of Huntington's disease. J Comp Neurol 1997; 387: 96-113.
181. Emerich D et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386: 395-399.
182. Ona V et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999; 399: 263-267.
183. Andrews T, Brooks D Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Mol Med Today 1998; 4: 532-539.
184. Campbell K, Olsson M, Bjorklund A. Regional incorporation and site-specific differentiation of striatal precursors transplanted to the embryonic forebrain ventricle. Neuron 1995; 15: 1259-1273.
185. Olsson M et al. Extensive migration and target innervation by striatal precursors after grafting into neonatal striatum. Neuroscience 1997, 79. 57-78.
186. Bjorklund A et al. Functional capacity of striatal transplants in the rat Huntington model. In: Dunnett S, Bjorklund A (eds). Functional Neuronal Transplantation. Raven Press: New York, 1994, pp 157-197.
187. Isacson O et al. Functional neuronal replacement by grafted striatal neurons in the ibotenic acid-lesioned rat striatum. Nature 1984; 311: 458-460.
188. Tuszynski MH et al. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy 1996; 3: 305-314.
189. Tuszynski et al. Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition. Exp Neurol 1998; 154: 573-582
190. Aebischer P et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2: 696-699.
191. Haase G et al. Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuropathy depends on the route of delivery. Ann Neurol 1999;
192. Gimenez y Ribotta M et al. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res 1997, 48: 281-285.
193. Mohajeri M, Figlewicz D, Bohn M. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 1999; 10. 1853-1866.
194. Pechan P et al. Gene therapy for ischemic stroke. In. Chiocca E, Breakefield XO (eds). Gene Therapy for Neurological Disorders and Brain Tumors. Human Press: Totowa, NJ, 1998, pp 397-407.
195. Linnik M, Zahos M, Geschwind M, Federoff H. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26: 1670-1675.
196. Lawrence MS et al. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Met 1997; 17: 740-744.
197. Betz A, Yang G, Davidson B Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Met 1995; 15: 547-551.
198. Yang G et al. Attenuation of ischemic inflammatory response in mouse brain using an adenovirus vector to induce overexpression of interleukin-1 receptor antagonist. J Cereb Blood Flow Met 1998; 18: 840-847
199. Xu D et al. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nature Med 1997; 3: 997-1004.
200. Yenari MA et al. Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy. Ann Neurol 1988; 44: 584-591.
201. Muhonene M et al. Gene transfer to cerebral blood vessels after subarachnoid hemorrhage. Stroke 1997; 28: 822-828.
202. Pechan P et al. Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. Neuroreport 1995; 6: 669-672.
203. Kramm CM et al. Gene therapy for brain tumors. Brain Pathol 1995; 5: 345-381.
204. Weyerbrock A, Oldfield EH. Gene transfer technologies for malignant ghomas. Curr Opin Oncol 1999; 11: 168-173.
205. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res 1986; 56: 5276-5281.
206. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
207. Aghi M et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
208. Wei MX et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
209. Manome Y et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med 1996; 2. 567-573.
210. Maisonpierre PC et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
211. Milauer B et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-578.
212. Paulus W, Baur I, Beutler AS, Reeves SA. Diffuse brain invasion of glioma cells requires beta 1 integrins. Lab Invest 1996, 75: 819-826.
213. Weston BW et al. Expression of human alpha(1,3) fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells Cance Res 1999; 59: 2127-2135.
214. Kim JYH et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999; 59: 711-719.
215. Yu J, Burwick J, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997, 8: 1065-1072.
216. Herrlinger U et al. Vaccination for experimental gliomas using GM-CSF-rransduced glioma cells. Cancer Gene Ther 1997; 4: 345-352.
217. Kikuchi T et al. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 1999; 80: 425-430.
218. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
219. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
220. Walczak H et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999; 5: 157-163.
221. Kondo S et al. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogens 1998; 16: 3323-3330.
222. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998; 58: 4871-1879.
223. Bateman A et al. Fusogenic membrane glyroproteins as a novel class of therapeutic genes for the gene therapy of cancer. ASGT Meeting, 1999 Abst. No. 687.
224. Birkenmeier EH et al. Murine mucopolysaccharidosis type VII Characterization of a mouse with beta-glucuromdase deficiency. J Clin Invest 1989; 83: 1256-1258.
225. Wolfe JH, Deshmane SL, Fraser NW. Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1992; 1: 379-384.
226. Ghodsi A et al. Extensive beta-glucuronidase activity in murine central nervous system after asdenovirus-mediacted gene transfer to brain. Hum Gene Ther 1998; 9: 2331-2340.
227. Watson GL et al. Treatment of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus. Gene Therapy 1998; 5: 1642-1649.
228. Elliger S et al. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Therapy 1999; 6: 1175-1178.
229. Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999; 10: 1251-1257.
230. Kang W et al. Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res 1998; 792: 133-135.
231. Wilson SP et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes simplex virus. Proc Natl Acad Sci USA 1999; 96: 3211-3216.
232. McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP. Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci USA 1995; 92: 3249-3233
233. Cayouette M, Gravel C. Adenovirus-mediate gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene Ther 1997; 8: 423-430.
234. Bennett J et al. Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse. Gene Therapy 1998; 5: 1156-1164.
235. Bennett J et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nature Med 1996, 2: 649-654.
236. Jomary C et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Therapy 1997; 4: 683-690.
237. Kafri T. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
238. Takahashi M, Miyoshi H, Verma IM, Gage FH. Rescue from photoreceptor degeneration in the rd nouse by human immunodeficiency virus vector-mediated gene transfer. J Virol 1999; 73: 7812-7816.
239. Noebels JL. Targeting epilepsy genes. Neuron 1996; 16: 241-244.
240. Robert JJ et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases. Gene Therapy 1997; 4: 1237-1245.
241. Zhang LX et al. Lipofectin-facilitated transfer of cholecystokinin gene corrects behavioral abnormalities of rats with audiogenic seizures. Neuroscience 1997; 77: 15-22.
242. Geddes BJ, Harding TC, Lightman SL, Uney JB. Long-term gene therapy in the CNS: reversal of hypothalamic diabetes inspidus in the Brattleboro rats by using an adenovirus expressing arginine vasopressin. Nature Med 1997; 3: 1402-1405.
243. Margolis TP et al. Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology 1992; 189: 150-160.